Valid Insight
Valid Insight is a UK-based market access consultancy serving pharmaceutical, biotech, MedTech, and medical nutrition companies with pricing strategy, evidence synthesis, HTA support, and negotiation training across 40+ markets, operating as a subsidiary of the Bioscript Group since 2021.
- Company typePrivate
- Founded2016
- HeadquartersMacclesfield, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Valid Insight does
Valid Insight is a UK-based specialist market access consultancy serving life sciences companies across the full product lifecycle, from early development through post-launch optimization. The firm delivers project-based engagements spanning market access strategy, pricing, evidence synthesis, value communication, HTA submission preparation, and negotiation training, targeting pharmaceutical, biotech, MedTech, diagnostics, and medical nutrition clients. Over the past three years, Valid Insight has delivered projects in 40+ markets, supported 30+ clients including 6 of the top 10 biopharmaceutical companies, and maintained multi-year relationships with 10+ clients exceeding five years of continuous engagement.
The firm's core technology and proprietary assets center on the Pricing and Market Access Simulator (PMAS), which models payer willingness-to-pay dynamics, and an in-house payer and clinical opinion leader database covering more than 2,000 stakeholders. Its Integrated Dynamic Negotiation Training Model provides country-specific workshops, competitor war-gaming, and mock negotiations with local payer experts. Valid Insight has been a subsidiary of the Bioscript Group since 2021, enabling integrated delivery across regulatory, data insights, and medical communications disciplines. The firm has expanded its mix to include approximately 20% MedTech and Diagnostics projects and roughly 17% medical nutrition projects, alongside a pharmaceutical core focused on immunology, neurology, ophthalmology, oncology, and rare diseases.
Valid Insight firmographics
Firmographics- Name
- Valid Insight
- Legal name
- Valid Insight Limited
- Website
- https://validinsight.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Valid Insight is a UK-based market access consultancy serving pharmaceutical, biotech, MedTech, and medical nutrition companies with pricing strategy, evidence synthesis, HTA support, and negotiation training across 40+ markets, operating as a subsidiary of the Bioscript Group since 2021.
- Ownership category
- akta.pro rank
Valid Insight industry classification
Industry- Product category
- Pharmaceutical Market Access Consulting
- NAICS
- Management, Scientific, and Technical Consulting Services (5416), Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Management Consulting Services (8742), Services-Engineering, Accounting, Research, Management (8700)
- akta.pro primary industry
- Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)
Keywords
Where Valid Insight is headquartered
LocationHeadquarters
- HQ city
- Macclesfield
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Valid Insight business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Strategic Market Access Consulting: Project-based consulting engagements across the product lifecycle, including market access strategy, pricing, evidence synthesis, value communication, and negotiation support. Engagements span early development through post-launch optimization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based engagements |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Valid Insight product offering
Product offeringCore offering
Valid Insight is a specialist market access consultancy that delivers strategic market access, pricing, evidence synthesis, value communication, and negotiation support services to life sciences companies across the product lifecycle — from early development through post-launch optimization. Services are delivered via project-based consulting engagements supported by proprietary tools including the Pricing and Market Access Simulator (PMAS) and an in-house database of 2,000+ payers and clinicians, with deep focus on pharmaceutical, biotech, MedTech, diagnostics, and medical nutrition clients.
Product overview
Valid Insight is a specialist market access consultancy that provides a suite of advisory services rather than a software platform. Their core offerings span the entire product lifecycle from early development through post-launch, including strategic market access consulting, value communication, payer research, pricing strategy, and evidence synthesis. Key proprietary offerings include the Pricing and Market Access Simulator (PMAS) for payer willingness-to-pay analysis, and an in-house database of over 2,000 payers and clinicians for primary research. The company specializes in pharmaceuticals (particularly immunology, neurology, ophthalmology, oncology, and rare disease), MedTech and diagnostics, medical nutrition, and environmental sustainability (ESG). Services include landscape assessments, HTA submissions, negotiation excellence training, tender strategy, value dossier development, and lifecycle management.
Differentiator
Problem solved
Functional benefit
Products and services
- Pricing and Market Access Simulator (PMAS) A proprietary simulator that models payer willingness-to-pay dynamics, providing insight into pricing thresholds and market access scenarios. Used to empower life sciences companies with informed access and pricing strategies.
- Strategic Market Access Consulting End-to-end market access advisory covering opportunity evaluation, value substantiation, stakeholder communication, access strategy fine-tuning, launch readiness, and post-launch lifecycle management for life sciences clients.
- Evidence Synthesis and Value Communication Development of evidence-based value narratives, value dossiers, manuscripts, objection handlers, and economic models designed for HTA bodies, payers, and clinicians in pharmaceutical, MedTech, and medical nutrition contexts.
- Negotiation Training and Excellence Workshops Country-specific facilitated workshops equipping affiliate teams with negotiation skills, competitor war-gaming, and mock negotiations led by local payer experts, often delivered across multiple affiliate markets.
- Primary Payer and Clinician Research Primary market research with payers, hospital pharmacists, and clinical opinion leaders to surface insights on pricing, positioning, evidence requirements, and stakeholder engagement strategies.
- HTA and Reimbursement Submission Support Preparation of HTA submissions, reimbursement dossiers, objection handlers, and tender management support for submissions to bodies such as NICE, HAS, G-BA, and WHO.
Quantifiable outcome
- Projects delivered in 40+ markets
- +2 more outcomes
Companies that use Valid Insight
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
Valid Insight technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Valid Insight partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Bioscript GroupcoreValid Insight joined the Bioscript Group in 2021, gaining access to a network of experts in data insights, regulatory, and medical communications. This enables integrated project delivery with smooth knowledge transfer and cohesive strategy across market access, regulatory, and medical initiatives.
- Informa Pharma IntelligenceminorPartnered in 2019 to host a roundtable at BIO-Europe focusing on best practices in payer engagement, gathering senior leaders from pharmaceutical and healthcare industries. Results published as whitepaper in early 2020.
- Bioscript Data Insights (BDI) TeamcoreInternal partnership within Bioscript Group combining payer-first thinking with data-driven analytics from the BDI team to help clients set products on optimal market access trajectories.
Scale indicators13 records
Recent moves4 records
Expansion highlights5 records
Valid Insight competitors and assessment
Company assessmentDirect peers
- PRMA Consulting: PRMA Consulting is a specialist market access consultancy serving biopharmaceutical clients with pricing, reimbursement, and evidence synthesis services across global markets. It is the closest direct competitor to Valid Insight in size, scope, and therapeutic-area breadth.
- Mtech Access: Mtech Access is a UK-based boutique market access consultancy offering strategic pricing, reimbursement, and HTA submission support to life sciences companies. Its service portfolio and target client base overlap almost entirely with Valid Insight's core offering.
- Avalere Health: Avalere Health is a US-headquartered healthcare consultancy with deep market access, HTA, and value-communication practices serving biopharma and MedTech. It competes with Valid Insight on global payer evidence and pricing strategy mandates.
- Putnam Associates: Putnam Associates is a strategy consultancy focused on biopharma pricing, market access, and launch strategy. Its boutique positioning and therapeutic-area depth make it a direct peer for Valid Insight's pricing and access strategy work.
- MAP BioPharma: MAP BioPharma is a UK-based market access consultancy offering pricing, reimbursement, and HTA support to pharma and MedTech clients. Its service offering, geography, and client mix closely mirror Valid Insight's niche positioning.
- Validant: Validant is a regulatory and market access consultancy serving life sciences companies with pricing, reimbursement, and launch readiness services. Its focus and service portfolio overlap directly with Valid Insight's strategic access engagements.
Broad incumbents
- Evidera (PPD / Thermo Fisher): Evidera, part of Thermo Fisher's PPD clinical research business, provides evidence synthesis, HTA, and market access services alongside broader CRO capabilities. It is a larger, more diversified incumbent competing for the same payer evidence and value communication work.
- Charles River Associates (Life Sciences): CRA's Life Sciences practice offers pricing, market access, and commercial strategy consulting to global biopharma. As a broader consulting firm, it overlaps with Valid Insight on strategic pricing and access engagements but at greater scale and with different delivery economics.
- Syneos Health Consulting: Syneos Health Consulting provides market access, pricing, and value strategy services integrated with its clinical and commercial CRO offerings. It competes with Valid Insight on biopharma access mandates, particularly those requiring global, multi-workstream delivery.
- IQVIA (Real World Evidence / Market Access): IQVIA operates one of the largest market access and pricing practices globally, combining proprietary data assets with consulting delivery. It is the dominant incumbent against which Valid Insight competes for large, multi-region biopharma mandates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Valid Insight social profiles
Digital presenceValid Insight financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valid Insight leadership team
Management profileNumber of profiles
Profiles6 records
Valid Insight funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valid Insight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valid Insight
What does Valid Insight do?
Valid Insight is a specialist market access consultancy that delivers strategic market access, pricing, evidence synthesis, value communication, and negotiation support services to life sciences companies across the product lifecycle — from early development through post-launch optimization. Services are delivered via project-based consulting engagements supported by proprietary tools including the Pricing and Market Access Simulator (PMAS) and an in-house database of 2,000+ payers and clinicians, with deep focus on pharmaceutical, biotech, MedTech, diagnostics, and medical nutrition clients.
Is Valid Insight a public or private company?
Valid Insight is a private company. It is classified as corporate owned and is currently operating.
When was Valid Insight founded?
Valid Insight was founded in 2016. It employs 11 to 50 people.
Where is Valid Insight based?
Valid Insight is headquartered in Macclesfield, United Kingdom, in the Europe region.
How does Valid Insight make money?
One revenue line is on record: strategic Market Access Consulting.
Who are Valid Insight's main competitors?
Direct peers on record are PRMA Consulting, Mtech Access, Avalere Health, Putnam Associates, MAP BioPharma and Validant. Broad incumbents are Evidera (PPD / Thermo Fisher), Charles River Associates (Life Sciences), Syneos Health Consulting and IQVIA (Real World Evidence / Market Access).
Does Valid Insight have an API?
No public API is recorded for Valid Insight.
What industry is Valid Insight in?
Valid Insight's product category is Pharmaceutical Market Access Consulting. Its primary akta.pro industry code is HLAGAOAN, Market Access, Pricing & Reimbursement (Evidence Generation) FSP. Its NAICS code is 5416 and its SIC code is 8742.